Trials / Conditions / Proteinuric Kidney Disease
Proteinuric Kidney Disease
5 registered clinical trials studyying Proteinuric Kidney Disease — 4 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria NCT07224776 | Brigham and Women's Hospital | Phase 1 |
| Recruiting | A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease NCT06830629 | Maze Therapeutics | Phase 2 |
| Recruiting | Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities NCT06794996 | Vertex Pharmaceuticals Incorporated | Phase 2 |
| Recruiting | Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney NCT05312879 | Vertex Pharmaceuticals Incorporated | Phase 2 / Phase 3 |
| Terminated | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney NCT01129557 | Columbia University | Phase 4 |